Search - tctmd.com

Displaying 61 - 80 of 223

Sort: Relevancy | Date

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

Leaflet Restriction After TAVR: Two Hospitals Tracking Patients Find Similar Rates of the Phenomenon

Shelley Wood

September 20, 2016

News Conference News ESC 2016

Valve Thrombosis After TAVR Linked to Larger Device Size, Lack of Warfarin Therapy

Todd Neale

September 02, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2016

Caitlin E. Cox

September 01, 2016

News Daily News

较低风险患者 TAVR 后生存率优于手术组，没有“风险升高”

L.A. McKeown

August 24, 2016

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

News Daily News

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

L.A. McKeown

August 24, 2016

News Daily News

Mejor Supervivencia y Ausencia de ‘Tendencia de Riesgo’ para TAVR vs Cirugía en Pacientes de Menor Riesgo

L.A. McKeown

August 24, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Daily News

Blood Test May Be Useful for Detecting Aortic Regurgitation During TAVR

L.A. McKeown

July 27, 2016

News Daily News

Combining Off-Pump CABG and Transaortic TAVR May Be an Option in Some Cases

Todd Neale

July 14, 2016

News Daily News

TAVR 可用于治疗二尖瓣主动脉瓣狭窄，但与永久性起搏器植入率更高相关联

Michael O'Riordan

July 05, 2016

News Daily News

TAVR for Bicuspid Aortic Valve Stenosis Feasible, but Associated With Higher Rate of Permanent Pacemaker Implantation

Michael O'Riordan

July 05, 2016

News Daily News

La Intervención TAVR para el Manejo de la Estenosis de la Válvula Aórtica Bicúspide es Viable pero se asocia a un Índice Más Alto de Implantación de Marcapasos Permanente

Michael O'Riordan

July 05, 2016

News Daily News

大规模 Meta 分析显示，TAVR 与手术 30 天和 1 年死亡率相当

Michael O'Riordan

June 07, 2016

News Daily News

Según un Gran Meta Análisis Parecida Mortalidad al cabo de 30 Días y 1 Año con TAVR Versus Cirugía

Michael O'Riordan

June 07, 2016

News Daily News

More Proof of Declining Paravalvular Regurgitation With Newest Balloon-Expandable TAVR Devices

Shelley Wood

June 07, 2016

News Daily News

Equivalent Mortality at 30 Days and 1 Year With TAVR vs Surgery, Says Large Meta-analysis

Michael O'Riordan

June 07, 2016

News Conference News EuroPCR 2016

Studies Highlight Permanent Pacemaker Rates Among New-Generation TAVR Devices

Michael O'Riordan

May 23, 2016

News Conference News EuroPCR 2016

‘Signal’ of Poor Durability Seen With First-Generation TAVR Devices

Caitlin E. Cox

May 17, 2016

Advertisement

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Leaflet Restriction After TAVR: Two Hospitals Tracking Patients Find Similar Rates of the Phenomenon

Valve Thrombosis After TAVR Linked to Larger Device Size, Lack of Warfarin Therapy

TCTMD’s Top 10 Most Popular Stories for August 2016

较低风险患者 TAVR 后生存率优于手术组，没有“风险升高”

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

Mejor Supervivencia y Ausencia de ‘Tendencia de Riesgo’ para TAVR vs Cirugía en Pacientes de Menor Riesgo

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Blood Test May Be Useful for Detecting Aortic Regurgitation During TAVR

Combining Off-Pump CABG and Transaortic TAVR May Be an Option in Some Cases

TAVR 可用于治疗二尖瓣主动脉瓣狭窄，但与永久性起搏器植入率更高相关联

TAVR for Bicuspid Aortic Valve Stenosis Feasible, but Associated With Higher Rate of Permanent Pacemaker Implantation

La Intervención TAVR para el Manejo de la Estenosis de la Válvula Aórtica Bicúspide es Viable pero se asocia a un Índice Más Alto de Implantación de Marcapasos Permanente

大规模 Meta 分析显示，TAVR 与手术 30 天和 1 年死亡率相当

Según un Gran Meta Análisis Parecida Mortalidad al cabo de 30 Días y 1 Año con TAVR Versus Cirugía

More Proof of Declining Paravalvular Regurgitation With Newest Balloon-Expandable TAVR Devices

Equivalent Mortality at 30 Days and 1 Year With TAVR vs Surgery, Says Large Meta-analysis

Studies Highlight Permanent Pacemaker Rates Among New-Generation TAVR Devices

‘Signal’ of Poor Durability Seen With First-Generation TAVR Devices

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content